Survival Impact of Inflammation-based Prognostic Scores in Metastatic or Unresectable Esophageal Cancer Treated With Pembrolizumab Plus Chemotherapy.
Sugase T, Kanemura T, Takeoka T, Matsuura N, Masuike Y, Shinno N, Hara H, Kitakaze M, Kubo M, Mukai Y, Sueda T, Hasegawa S, Akita H, Nishimura J, Wada H, Yasui M, Omori T, Miyata H.
Sugase T, et al. Among authors: mukai y.
J Immunother. 2024 Jun 3. doi: 10.1097/CJI.0000000000000529. Online ahead of print.
J Immunother. 2024.
PMID: 38828771